473 related articles for article (PubMed ID: 30619376)
1. Interleukin-33 in Malignancies: Friends or Foes?
Shen JX; Liu J; Zhang GJ
Front Immunol; 2018; 9():3051. PubMed ID: 30619376
[TBL] [Abstract][Full Text] [Related]
2. Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight.
Andreone S; Gambardella AR; Mancini J; Loffredo S; Marcella S; La Sorsa V; Varricchi G; Schiavoni G; Mattei F
Front Immunol; 2020; 11():571593. PubMed ID: 33329534
[TBL] [Abstract][Full Text] [Related]
3. IL-33/ST2 as a potential target for tumor immunotherapy.
Jiang W; Lian J; Yue Y; Zhang Y
Eur J Immunol; 2021 Aug; 51(8):1943-1955. PubMed ID: 34131922
[TBL] [Abstract][Full Text] [Related]
4. The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine.
Fournié JJ; Poupot M
Front Immunol; 2018; 9():2506. PubMed ID: 30416507
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-33 and ST2 Signaling in Tumor Microenvironment.
Hong J; Kim S; Lin PC
J Interferon Cytokine Res; 2019 Jan; 39(1):61-71. PubMed ID: 30256696
[TBL] [Abstract][Full Text] [Related]
6. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
[TBL] [Abstract][Full Text] [Related]
7. ST2 Signaling in the Tumor Microenvironment.
Chang CP; Hu MH; Hsiao YP; Wang YC
Adv Exp Med Biol; 2020; 1240():83-93. PubMed ID: 32060890
[TBL] [Abstract][Full Text] [Related]
8. Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8
Chen H; Chen Y; Liu H; Que Y; Zhang X; Zheng F
Front Immunol; 2018; 9():1179. PubMed ID: 29896199
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
10. [Interleukin-33: Friend or Enemy in the Fight against Tumors?].
Gorbacheva AM; Mitkin NA
Mol Biol (Mosk); 2019; 53(5):774-789. PubMed ID: 31661477
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.
Qi L; Zhang Q; Miao Y; Kang W; Tian Z; Xu D; Xiao W; Fang F
Int J Cancer; 2020 Mar; 146(5):1421-1434. PubMed ID: 31709531
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus prevents the subsequent development of ovalbumin-induced allergic responses by inhibiting ILC2 via the IL-33/ST2 pathway.
Wang D; Bai S; Cui Y; Zhao N; Qi F; Liu J; Zeng S; Xu L; Hu H; Liu B
Immunotherapy; 2018 Sep; 10(12):1065-1076. PubMed ID: 30027786
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family.
Cayrol C; Girard JP
Immunol Rev; 2018 Jan; 281(1):154-168. PubMed ID: 29247993
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-33 and Behçet disease: Another cytokine among others.
Hamzaoui K; Bouali E; Hamzaoui A
Hum Immunol; 2015 May; 76(5):301-6. PubMed ID: 25814446
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.
Lu B; Yang M; Wang Q
J Mol Med (Berl); 2016 May; 94(5):535-43. PubMed ID: 26922618
[TBL] [Abstract][Full Text] [Related]
18. Emerging Roles of IL-33/ST2 Axis in Renal Diseases.
Chen WY; Li LC; Yang JL
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28387719
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-33 in atopic dermatitis.
Imai Y
J Dermatol Sci; 2019 Oct; 96(1):2-7. PubMed ID: 31455506
[TBL] [Abstract][Full Text] [Related]
20. Targeting interleukin-22 for cancer therapy.
Markota A; Endres S; Kobold S
Hum Vaccin Immunother; 2018; 14(8):2012-2015. PubMed ID: 29617184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
